ANI Pharmaceuticals Inc (ANIP) stock
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$71.47+1.48 (+2.11%)
Close on Nov 18, 2026Market cap $1.64BP/E 15.2Yield –
ANI Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ANI Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $150.36M, up 889.9% year over year. For fiscal 2025 it was $111.09M, up 18922.8% from the year before. Over ten years it grew 13.0% a year on average. The highest annual figure on record is $111.09M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.09M | +18922.8% |
| FY2024 | Dec 31, 2024 | $584.00K | -98.8% |
| FY2023 | Dec 31, 2023 | $46.97M | – |
| FY2022 | Dec 31, 2022 | -$35.28M | – |
| FY2021 | Dec 31, 2021 | -$39.79M | – |
| FY2020 | Dec 31, 2020 | -$16.02M | -198.0% |
| FY2019 | Dec 31, 2019 | $16.35M | -53.8% |
| FY2018 | Dec 31, 2018 | $35.36M | +24.8% |
| FY2017 | Dec 31, 2017 | $28.33M | +41.1% |
| FY2016 | Dec 31, 2016 | $20.08M | -38.6% |
| FY2015 | Dec 31, 2015 | $32.70M | +63.5% |
| FY2014 | Dec 31, 2014 | $20.01M | +2127.8% |
| FY2013 | Dec 31, 2013 | $898.00K | – |
| FY2012 | Dec 31, 2012 | -$42.00K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $40.46M | +191.2% |
| Q1 FY2026 | Mar 31, 2026 | $38.89M | +48.5% |
| Q4 FY2025 | Dec 31, 2025 | $34.77M | – |
| Q3 FY2025 | Sep 30, 2025 | $36.24M | – |
| Q2 FY2025 | Jun 30, 2025 | $13.89M | +168.8% |
| Q1 FY2025 | Mar 31, 2025 | $26.19M | +29.0% |
| Q4 FY2024 | Dec 31, 2024 | -$4.38M | -165.1% |
| Q3 FY2024 | Sep 30, 2024 | -$20.52M | -214.3% |
| Q2 FY2024 | Jun 30, 2024 | $5.17M | -58.3% |
| Q1 FY2024 | Mar 31, 2024 | $20.31M | +105.3% |
| Q4 FY2023 | Dec 31, 2023 | $6.73M | +269.6% |
| Q3 FY2023 | Sep 30, 2023 | $17.95M | – |
| Q2 FY2023 | Jun 30, 2023 | $12.40M | – |
| Q1 FY2023 | Mar 31, 2023 | $9.90M | – |
| Q4 FY2022 | Dec 31, 2022 | $1.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.20M | -730.4% |
| Q4 FY2021 | Dec 31, 2021 | -$23.72M | -7267.1% |
| Q3 FY2021 | Sep 30, 2021 | -$3.56M | -227.1% |
| Q2 FY2021 | Jun 30, 2021 | -$15.55M | – |
| Q1 FY2021 | Mar 31, 2021 | $3.05M | – |
| Q4 FY2020 | Dec 31, 2020 | $331.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $2.80M | -61.8% |
| Q2 FY2020 | Jun 30, 2020 | -$11.31M | -221.7% |
| Q1 FY2020 | Mar 31, 2020 | -$7.84M | -278.1% |
| Q4 FY2019 | Dec 31, 2019 | -$4.67M | -140.8% |
| Q3 FY2019 | Sep 30, 2019 | $7.33M | -27.5% |
| Q2 FY2019 | Jun 30, 2019 | $9.29M | +27.9% |
| Q1 FY2019 | Mar 31, 2019 | $4.40M | -32.7% |
| Q4 FY2018 | Dec 31, 2018 | $11.45M | +55.1% |
| Q3 FY2018 | Sep 30, 2018 | $10.11M | +8.4% |
| Q2 FY2018 | Jun 30, 2018 | $7.26M | +3.8% |
| Q1 FY2018 | Mar 31, 2018 | $6.54M | +41.3% |
| Q4 FY2017 | Dec 31, 2017 | $7.38M | +468.5% |
| Q3 FY2017 | Sep 30, 2017 | $9.33M | +17.8% |
| Q2 FY2017 | Jun 30, 2017 | $6.99M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.30M | – |
| Q3 FY2016 | Sep 30, 2016 | $7.92M | – |
See a number that looks wrong?